Shares of Sun Pharmaceutical Industries Ltd gained 2.5 percent on January 31 after the company reported an 11% rise in its consolidated net profit to Rs 2,058.80 crore in the December quarter. The pharma major had reported a net profit of ₹1,852 crores in the December quarter of last year. Consolidated net sales for the quarter increased 11.41% from a year ago to Rs 9,814.17 crore. Total cost advanced 12% to Rs 7,829.38 crore. The company's board has also declared an interim dividend of ₹7 for the financial year ending on March 31, 2022. Operating EBITDA margin declined sharply to 17.12% in the quarter from 20.43% a quarter ago and 20.97% a year ago.
The sale of formulations in the domestic market during the third quarter was at ₹3,167 crores, up by 15% over last year and accounting for 32% of total sales.
Read more